Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
DLH (NASDAQ:DLHC) serves federal government clients throughout the United States a...
DLH (NASDAQ:DLHC) serves federal government cli...
Wright Medical Group N.V. is a global medical device company focused on Extremitie...
Wright Medical Group N.V. is a global medical d...
Intercept is a biopharmaceutical company focused on the development and commercial...
Intercept is a biopharmaceutical company focuse...
Assembly Biosciences is advancing a new class of oral therapeutics for the treatme...
Assembly Biosciences is advancing a new class o...
Acceleron is dedicated to the discovery and development of innovative, life-changi...
Acceleron is dedicated to the discovery and dev...
Reliv International, based in Chesterfield, MO, produces nutritional supplements t...
Reliv International, based in Chesterfield, MO,...
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing no...
Madrigal Pharmaceuticals is a clinical-stage bi...
Join the National Investor Network and get the latest information with your interests in mind.